Volume 11, Number 6—June 2005
Dispatch
Macrolide- and Telithromycin-resistant Streptococcus pyogenes, Belgium, 1999–20031
Table A1
Antimicrobial* | Constitutive (n = 209) |
M (n = 279) |
Inducible (n = 18) |
||||||
---|---|---|---|---|---|---|---|---|---|
Range | MIC50 | MIC90 | Range | MIC50 | MIC90 | Range | MIC50 | MIC90 | |
Erythromycin | 4–>512 | >512 | >512 | 1–128 | 8 | 16 | 1–>512 | 4 | >512 |
Clindamycin | 2–>512 | >512 | >512 | ≤0.03–4 | 0.06 | 1 | 0.125–256 | 0.75 | 128 |
Clarithromycin | 1–>512 | >512 | >512 | 1–256 | 8 | 16 | 0.5–>512 | 2 | >512 |
Azithromycin | 4–>512 | >512 | >512 | 1–128 | 8 | 16 | 0.5–>512 | 4 | >512 |
Tetracycline | 0.06–128 | 32 | 64 | ≤0.03–64 | 0.25 | 0.5 | 0.06–64 | 0.5 | 64 |
Telithromycin† | 0.0075–32 | 1 | 8 | 0.0075–2 | 0.5 | 0.5 | 0.003–4 | 0.06 | 0.5 |
*Dilution range of 0.03 to 512 μg/mL for all antimicrobial agents except telithromycin, which is 0.00375 to 64 μg/mL.
†Breakpoints for telithromycin, susceptible ≤1μg/mL, resistant ≥4 μg/mL.
1A preliminary account of this work was presented at the 44th Interscience Conference on Antimicrobial Agents and Chemotherapy, October 30–November 2, 2004, Washington DC, USA.
Page created: April 24, 2012
Page updated: April 24, 2012
Page reviewed: April 24, 2012
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.